A Single-center, Single-dose, Randomized, Double-blind, Double-dummy, Placebo-controlled, Positive-controlled, Four-way Crossover Study to Investigate the Effect of Danoprevir With Low Dose Ritonavir (DNV/r) on the QT/QTc Interval in Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 10 Jun 2016
At a glance
- Drugs Danoprevir (Primary) ; Moxifloxacin; Ritonavir
- Indications Bacterial infections; Hepatitis C
- Focus Adverse reactions
- Sponsors Roche
- 01 Aug 2013 Results published in Drug Development Research.
- 21 May 2012 Actual end date changed from Feb 2012 to Apr 2012 as reported by ClinicalTrials.gov.
- 18 Apr 2012 Actual end date 1 Feb 2012 added as reported by ClinicalTrials.gov.